Katharina Elisabeth Blankart : Citation Profile


Are you Katharina Elisabeth Blankart?

Berner Fachhochschule (95% share)
Universität Duisburg-Essen (5% share)

4

H index

0

i10 index

42

Citations

RESEARCH PRODUCTION:

19

Articles

4

Papers

RESEARCH ACTIVITY:

   12 years (2011 - 2023). See details.
   Cites by year: 3
   Journals where Katharina Elisabeth Blankart has often published
   Relations with other researchers
   Recent citing documents: 5.    Total self citations: 13 (23.64 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pfi221
   Updated: 2024-12-03    RAS profile: 2024-05-02    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Lichtenberg, Frank (3)

Authors registered in RePEc who have co-authored more than one work in the last five years with Katharina Elisabeth Blankart.

Is cited by:

LEVAGGI, ROSELLA (3)

Lancsar, Emily (2)

Gu, Yuanyuan (2)

Mortimer, Duncan (2)

Leporatti, Lucia (2)

Mammi, Irene (1)

Lippi Bruni, Matteo (1)

Hu, Min (1)

Ma, Ching-to (1)

Iversen, Tor (1)

Lichtenberg, Frank (1)

Cites to:

Devlin, Nancy (10)

Lichtenberg, Frank (8)

Leidl, Reiner (8)

Leidl, Reiner (8)

Propper, Carol (7)

Stargardt, Tom (7)

Parkin, David (7)

Laudicella, Mauro (6)

Atella, Vincenzo (6)

Belotti, Federico (6)

Gaynor, Martin (6)

Main data


Where Katharina Elisabeth Blankart has published?


Journals with more than one article published# docs
Health Policy6
The European Journal of Health Economics3
Medical Decision Making2
IJERPH2

Recent works citing Katharina Elisabeth Blankart (2024 and 2023)


YearTitle of citing document
2023Quantity versus quality in publication activity: knowledge production at the regional level. (2023). Peker, Irina ; Gareev, Timur. In: Papers. RePEc:arx:papers:2311.08830.

Full description at Econpapers || Download paper

2023Market diffusion of biosimilars in off-patent biologic drug markets across Europe. (2023). Steiner, Isa Maria ; Bohm, Anna-Katharina ; Stargardt, Tom. In: Health Policy. RePEc:eee:hepoli:v:132:y:2023:i:c:s0168851023001033.

Full description at Econpapers || Download paper

2023Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation. (2022). Czypionka, Thomas ; Rohrling, Gerald ; Reiss, Miriam ; Pock, Markus ; Berger, Michael. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:116928.

Full description at Econpapers || Download paper

2023Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms. (2023). Czypionka, Thomas ; Rohrling, Gerald ; Reiss, Miriam ; Pock, Markus ; Berger, Michael. In: International Journal of Health Economics and Management. RePEc:kap:ijhcfe:v:23:y:2023:i:1:d:10.1007_s10754-022-09337-6.

Full description at Econpapers || Download paper

2023Does health technology assessment compromise access to pharmaceuticals?. (2023). Stargardt, Tom ; Bussgen, Melanie. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:24:y:2023:i:3:d:10.1007_s10198-022-01484-4.

Full description at Econpapers || Download paper

Works by Katharina Elisabeth Blankart:


YearTitleTypeCited
2021A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany In: CINCH Working Paper Series (since 2020).
[Full Text][Citation analysis]
paper0
.() In: .
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 0
paper
2023Policy as a strategy to innovate in health care? A content analysis of innovation policies in Germany, 1994–2017 In: International Journal of Health Planning and Management.
[Full Text][Citation analysis]
article0
2011A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention In: Health Policy.
[Full Text][Citation analysis]
article1
2012A systematic review of coverage decision-making on health technologies—Evidence from the real world In: Health Policy.
[Full Text][Citation analysis]
article9
2013Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis In: Health Policy.
[Full Text][Citation analysis]
article4
2016Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia In: Health Policy.
[Full Text][Citation analysis]
article8
2016Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark In: Health Policy.
[Full Text][Citation analysis]
article0
2016Dispensing behaviour of pharmacies in prescription drug markets In: Health Policy.
[Full Text][Citation analysis]
article0
In: .
[Full Text][Citation analysis]
article0
In: .
[Full Text][Citation analysis]
article1
2020Are patients more adherent to newer drugs? In: Health Care Management Science.
[Full Text][Citation analysis]
article2
2022The Effects of Off-label Drug Use on Disability and Medical Expenditure In: NBER Working Papers.
[Full Text][Citation analysis]
paper0
2022The effects of off-label drug use on disability and medical expenditure.(2022) In: Ruhr Economic Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 0
paper
In: .
[Full Text][Citation analysis]
article0
2013Link between Process and Appraisal in Coverage Decisions In: Medical Decision Making.
[Full Text][Citation analysis]
article0
2014Early Benefit Assessment of Pharmaceuticals in Germany In: Medical Decision Making.
[Full Text][Citation analysis]
article4
2014Analysing coverage decision-making: opening Pandora’s box? In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2016The diffusion of generics after patent expiry in Germany In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article4
2018The impact of physician-level drug budgets on prescribing behavior In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article4
2022Arzneimittel: Placebo bei Engpassbekämpfung In: Wirtschaftsdienst.
[Full Text][Citation analysis]
article0
2021Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe In: REGION.
[Full Text][Citation analysis]
article1
2020The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany In: Health Economics.
[Full Text][Citation analysis]
article3

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team